Overview

  • Product name
    Anti-FGFR1 (phospho Y766) antibody
    See all FGFR1 primary antibodies
  • Description
    Rabbit polyclonal to FGFR1 (phospho Y766)
  • Host species
    Rabbit
  • Specificity
    Detects endogenous levels of FGFR1 only when phosphorylated at tyrosine 766.
  • Tested applications
    Suitable for: IHC-P, ELISA, ICC/IF, WBmore details
  • Species reactivity
    Reacts with: Human
    Predicted to work with: Mouse, Rat
  • Immunogen

    Synthetic phosphopeptide from around the phosphorylation site of tyrosine 766 (QEYPLD) of human FGFR1

  • Positive control
    • Human breast carcinoma tissue This antibody gave a positive result when used in the following formaldehyde fixed cell lines: SKNSH.

Properties

Applications

Our Abpromise guarantee covers the use of ab59180 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
IHC-P Use at an assay dependent concentration.
ELISA 1/5000.
ICC/IF Use a concentration of 5 µg/ml.
WB 1/500 - 1/1000.

Target

  • Function
    Receptor for basic fibroblast growth factor. Receptor for FGF23 in the presence of KL (By similarity). A shorter form of the receptor could be a receptor for FGF1 (aFGF).
  • Tissue specificity
    Detected in astrocytoma, neuroblastoma and adrenal cortex cell lines. Some isoforms are detected in foreskin fibroblast cell lines, however isoform 17, isoform 18 and isoform 19 are not detected in these cells.
  • Involvement in disease
    Defects in FGFR1 are a cause of Pfeiffer syndrome (PS) [MIM:101600]; also known as acrocephalosyndactyly type V (ACS5). PS is characterized by craniosynostosis (premature fusion of the skull sutures) with deviation and enlargement of the thumbs and great toes, brachymesophalangy, with phalangeal ankylosis and a varying degree of soft tissue syndactyly.
    Defects in FGFR1 are a cause of idiopathic hypogonadotropic hypogonadism (IHH) [MIM:146110]. IHH is defined as a deficiency of the pituitary secretion of follicle-stimulating hormone and luteinizing hormone, which results in the impairment of pubertal maturation and of reproductive function.
    Defects in FGFR1 are the cause of Kallmann syndrome type 2 (KAL2) [MIM:147950]; also known as hypogonadotropic hypogonadism and anosmia. Anosmia or hyposmia is related to the absence or hypoplasia of the olfactory bulbs and tracts. Hypogonadism is due to deficiency in gonadotropin-releasing hormone and probably results from a failure of embryonic migration of gonadotropin-releasing hormone-synthesizing neurons. In some cases, midline cranial anomalies (cleft lip/palate and imperfect fusion) are present and anosmia may be absent or inconspicuous.
    Defects in FGFR1 are the cause of osteoglophonic dysplasia (OGD) [MIM:166250]; also known as osteoglophonic dwarfism. OGD is characterized by craniosynostosis, prominent supraorbital ridge, and depressed nasal bridge, as well as by rhizomelic dwarfism and nonossifying bone lesions. Inheritance is autosomal dominant.
    Defects in FGFR1 are the cause of trigonocephaly non-syndromic (TRICEPH) [MIM:190440]; also known as metopic craniosynostosis. The term trigonocephaly describes the typical keel-shaped deformation of the forehead resulting from premature fusion of the frontal suture. Trigonocephaly may occur also as a part of a syndrome.
    Note=A chromosomal aberration involving FGFR1 may be a cause of stem cell leukemia lymphoma syndrome (SCLL). Translocation t(8;13)(p11;q12) with ZMYM2. SCLL usually presents as lymphoblastic lymphoma in association with a myeloproliferative disorder, often accompanied by pronounced peripheral eosinophilia and/or prominent eosinophilic infiltrates in the affected bone marrow.
    Note=A chromosomal aberration involving FGFR1 may be a cause of stem cell myeloproliferative disorder (MPD). Translocation t(6;8)(q27;p11) with FGFR1OP. Insertion ins(12;8)(p11;p11p22) with FGFR1OP2. MPD is characterized by myeloid hyperplasia, eosinophilia and T-cell or B-cell lymphoblastic lymphoma. In general it progresses to acute myeloid leukemia. The fusion proteins FGFR1OP2-FGFR1, FGFR1OP-FGFR1 or FGFR1-FGFR1OP may exhibit constitutive kinase activity and be responsible for the transforming activity.
    Note=A chromosomal aberration involving FGFR1 may be a cause of stem cell myeloproliferative disorder (MPD). Translocation t(8;9)(p12;q33) with CEP110. MPD is characterized by myeloid hyperplasia, eosinophilia and T-cell or B-cell lymphoblastic lymphoma. In general it progresses to acute myeloid leukemia. The fusion protein CEP110-FGFR1 is found in the cytoplasm, exhibits constitutive kinase activity and may be responsible for the transforming activity.
  • Sequence similarities
    Belongs to the protein kinase superfamily. Tyr protein kinase family. Fibroblast growth factor receptor subfamily.
    Contains 3 Ig-like C2-type (immunoglobulin-like) domains.
    Contains 1 protein kinase domain.
  • Post-translational
    modifications
    Binding of FGF1 and heparin promotes autophosphorylation on tyrosine residues and activation of the receptor.
  • Cellular localization
    Membrane. Nucleus. Cytoplasm. Cytoplasmic vesicle
  • Information by UniProt
  • Database links
  • Alternative names
    • Basic fibroblast growth factor receptor 1 antibody
    • bFGF-R-1 antibody
    • BFGFR antibody
    • CD331 antibody
    • CEK antibody
    • FGFBR antibody
    • FGFR 1 antibody
    • FGFR-1 antibody
    • FGFR1 antibody
    • FGFR1/PLAG1 fusion antibody
    • FGFR1_HUMAN antibody
    • fibroblast growth factor receptor 1 antibody
    • FLG antibody
    • FLT-2 antibody
    • FLT2 antibody
    • Fms-like gene antibody
    • Fms-like tyrosine kinase 2 antibody
    • fms-related tyrosine kinase 2 antibody
    • HBGFR antibody
    • heparin-binding growth factor receptor antibody
    • HH2 antibody
    • HRTFDS antibody
    • hydroxyaryl-protein kinase antibody
    • KAL2 antibody
    • N-SAM antibody
    • OGD antibody
    • Proto-oncogene c-Fgr antibody
    see all

Images

  • All lanes : Anti-FGFR1 (phospho Y766) antibody (ab59180)

    Lane 1 : EGF-treated HepG2 cell extract
    Lane 2 : EGF-treated HepG2 cell extract with blocking phosphopeptide
  • Immunohistochemistry analysis of paraffin-embedded human breast carcinoma tissue using ab59180 with and without the addition of the synthetic phosphopeptide derived from human FGFR1 around the phosphorylation site of tyrosine 766.
  • ab59180 stained SKNSH cells. The cells were 4% formaldehyde fixed (10 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody ab59180 at 5µg/ml overnight at +4°C. The secondary antibody (green) was DyLight® 488 goat anti- rabbit (ab96899) IgG (H+L) used at a 1/1000 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM.

References

This product has been referenced in:
  • Bunney TD  et al. Disease Variants of FGFR3 Reveal Molecular Basis for the Recognition and Additional Roles for Cdc37 in Hsp90 Chaperone System. Structure 26:446-458.e8 (2018). Read more (PubMed: 29478821) »
  • Pinotsis N & Waksman G Structure of the WipA protein reveals a novel tyrosine protein phosphatase effector from Legionella pneumophila. J Biol Chem 292:9240-9251 (2017). Read more (PubMed: 28389563) »
See all 3 Publications for this product

Customer reviews and Q&As

1-5 of 5 Abreviews or Q&A

Answer

Thank you for contacting us.

I have conducted a search through our catalogue for antibodies against pFGFR1 and pFGFR4 which do no cross-react with the other FGFRs.

Ab59180 is specific against FGFR1 when it is phosphorilated at Tyr766. Similarly, ab59194 is specific against FGFR1 when it is phosphorilated at Tyr654, while ab52165 is specific against FGFR1 when it is phosphorilated at Tyr154.

These three antibodies do not bind to non-phosphorilated proteins. If you would send me the accession numbers or the exact protein sequences of other FGFRs that you are concerned with cross reactivity, I can align them with our immunogen sequence for sequence homology and possible cross reactivity.

We do have other alternatives (ab111124 and ab134043) against pFGFR1. However, these antibodies may also detect FGFR2, FGFR3 and FGFR4 phosphorilated at the equivalent sites. Although the antibodies have not been tested to determine if it detects these other endogenous forms, based on sequence homology reactivity would be expected.

Unfortunately, all the https://www.abcam.com/Search?Keywords=FGFR4+&fReset=1&pt=1&source=TopSearch&btnSearch=Search are against non phosphorilated forms, so I am afraid they would not fit your requirements.

Please do not hesitate to let me know whether you require a proforma, or any further assistance.

Read More

Answer

Thank you for your reply. I am sending a free of charge vial of ab109731 on the order *** which should arrive shortly. Please let me know if you have any questions or if there is anything else that we can do for you.  

Read More

Answer

Thank you for submitting your recent review of ab59180. I am sorry to see that the results were so poor with this antibody. I do have a couple of suggestions that might help improve the results, however we do fully guarantee our products in tested species and applications for 6 months after purchase, so I would be happy to send a replacement antibody or issue a credit or refund. As you mentioned, some of the extra bands on the blot may be isoforms of the protein. I would recommend blocking for at least an hour and reducing the protein load to around 20-30 ug of protein to reduce non-specific bands. Also using a phosphatase inhibitor cocktail can ensure that the protein is sufficiently phosphorylated. We have tested the antibody in HepG2 cells treated with EGF, so a phosphorylating treatment may be necessary to see a strong band in the siRNA control. Please let me know if these suggestions are helpful, or if you would like to receive a replacement, credit, or refund please send me your original order number and I will be happy to arrange that  for you. I look forward to hearing from you.

Read More
Application
Western blot
Sample
Human Cell lysate - whole cell (U87 (Glioblastoma))
Loading amount
50 µg
Specification
U87 (Glioblastoma)
Treatment
siRNA FGFR1
Gel Running Conditions
Reduced Denaturing (10%)
Blocking step
BSA as blocking agent for 20 minute(s) · Concentration: 5% · Temperature: 20°C

Abcam user community

Verified customer

Submitted Nov 30 2011

Answer

Thank you for contacting us. Indeed, crossreactivity is always a very important information for an antibody. Sequence alignment and experimental data can help to predict/determine this. We receive these antibodies from a collaborating laboratory. I have asked the laboratory to know how the specificity has been determined and whether crossreactivity has experimentally been assessed. The laboratory had not assessed this crossreactivity experimentally. They have run a blast with the exact immunogen sequences (to which I have no access) and does on that basis exclude any possible crossreaction with other proteins than FGFR1. The regions from which the respective peptide immunogen of the antibodies are ab52165 (Tyr154), ab59180 (Tyr 766) and ab59194 (Tyr654). Please find here the sequence alignment for FGFR1 with FGFR2: http://www.ebi.ac.uk/Tools/services/web_clustalw2/toolresult.ebi?tool=clustalw2&jobId=clustalw2-I20110907-091151-0127-47989414-oy For predicted crossreactivity with FGFR2: Comparison of the sequence with FGFR3 and FGFR1: http://www.ebi.ac.uk/Tools/services/web_clustalw2/toolresult.ebi?tool=clustalw2&jobId=clustalw2-I20110907-103134-0638-15807362-pg Sequence alignment of FGFR1 with FGFR4: http://www.ebi.ac.uk/Tools/services/web_clustalw2/toolresult.ebi?tool=clustalw2&jobId=clustalw2-I20110907-103350-0499-7232840-pg The sequence around Tyr154 has deletions in the FGFR2 and FGFR3 sequence when compared to the sequence of FGFR1, resulting therefore in a very poor alignment of that region. I hope this information is helpful to you. Please do not hesitate to contact us if you need any more advice or information.

Read More

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

Sign up